Cigarette smoking history predicts sensitivity to erlotinib: Results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC).

被引：0
|
作者：
Kris, MG
Sandler, A
Miller, V
Cespon, M
Zakowski, M
Pizzo, B
Venkatraman, E
Gomez, J
Johnson, D
Carbone, D
机构：
[1] Mem Sloan Kettering, New York, NY USA
[2] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7062
引用
收藏
页码：631S / 631S
页数：1
相关论文
共 50 条
  • [1] Phase II trial of erlotinib in patients with bronchioloalveolar carcinoma
    Sandler, A
    Kris, M
    Miller, V
    Carbone, D
    Pao, W
    Billheimer, D
    Tsao, A
    Patel, J
    Johnson, B
    Johnson, D
    [J]. LUNG CANCER, 2005, 49 : S38 - S39
  • [2] EGFR and KRAS mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial.
    Kris, MG
    Sandler, A
    Miller, VA
    Zakowski, MF
    Pao, W
    Tsao, A
    Patel, JD
    Johnson, DH
    Carbone, DP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 627S - 627S
  • [3] EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC):: Results of a prospective phase II trial.
    Miller, V. A.
    Zakowski, M.
    Riely, G. J.
    Pao, W.
    Ladanyi, M.
    Tsao, A. S.
    Sandler, A.
    Herbst, R.
    Kris, M. G.
    Johnson, D. H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 364S - 364S
  • [4] WHAT ARE THE DIFFERENCES BETWEEN BRONCHIOLOALVEOLAR CARCINOMA (BAC) AND ADENOCARCINOMA PATIENTS (P) WITH EGFR MUTATIONS WHEN TREATED WITH ERLOTINIB?
    Reguart, N.
    Cardenal, F.
    Porta, R.
    Provencio, M.
    Gonzalez-Larriba, J. L.
    Pallares, C.
    Massuti, B.
    Insa, A.
    Lopez-Vivanco, G.
    Rosell, R.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 99 - 99
  • [5] Phase II trial of pemetrexed in patients with selected stage IIIB/IV bronchioloalveolar carcinoma
    Ho, Cheryl
    Ross, Helen
    Davies, Angela
    [J]. CLINICAL LUNG CANCER, 2006, 8 (03) : 220 - 222
  • [6] Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC)
    Hainsworth, JD
    Sosman, JA
    Spigel, DR
    Schwert, RC
    Carrell, DL
    Hubbard, F
    Greco, FA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 382S - 382S
  • [7] A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma
    Bedano, P. M.
    Perkins, S.
    Burns, M.
    Kessler, K.
    Nelson, R.
    Schneider, B. P.
    Risley, L.
    Dropcho, S.
    Loehrer, P. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer
    Gravis, G.
    Bladou, F.
    Salem, N.
    Goncalves, A.
    Esterni, B.
    Walz, J.
    Bagattini, S.
    Marcy, M.
    Brunelle, S.
    Viens, P.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (09) : 1624 - 1628
  • [9] A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956)
    Scagliotti, GV
    Smit, E
    Bosquee, L
    O'Brien, M
    Ardizzoni, A
    Zatloukal, P
    Eberhardt, W
    Smid-Geirnaerdt, M
    de Bruin, HG
    Dussenne, S
    Legrand, C
    Giaccone, G
    [J]. LUNG CANCER, 2005, 50 (01) : 91 - 96
  • [10] Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma
    Propper, D.
    Davidenko, I.
    Bridgewater, J.
    Kupcinskas, L.
    Fittipaldo, A.
    Hillenbach, C.
    Klughammer, B.
    Ducreux, M.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (07) : 1384 - 1390
12345